Bin Zou
Founder & Chief Executive Officer Axcynsis Therapeutics
Bin Zou is a seasoned executive and has helmed many leadership positions. He is currently an Adjunct Associate Professor at National University of Singapore. Previously, he served as Managing Director at Trinity Innovation Bioventure Singapore (TIBS) and was the CEO of Shanghai Blueray Biopharma where he successfully led the team to develop several candidates into investigational new drug (IND) stage. Prior to his venture, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease where he spearheaded the team to the discovery of Phase II clinical trials drug NITD609. He is the author to more than 25 peer reviewed publications.
Seminars
Monday 8th March 2027
Advancing a Novel Payload AxcynDOT & Its Application in First-in-Class Anti-CLDN6-ADC
2:00 pm
- Outlining the AxcynDOT payload technology to overcome drug resistance
- Design and developing AT-03, a first-in-class anti CLDN6 ADC
- Presenting key pre-clinical and clinical development insights from AT03
